Kling Biotherapeutics
What They Do
Kling discovers and develops antibody-based therapeutics by scanning the immune repertoires of patients who have had remarkable outcomes. The company’s proprietary B cell immortalization technology enables functional screening of B cells, leading to the unbiased discovery of novel targets and pathways.
This platform has generated a rich pipeline of therapeutic antibodies and antibody-derived products, including KBA-1412, which is in human clinical testing for a range of cancers with high unmet patient need.
Why We Invested
Time BioVentures founded Kling in 2021 in Amsterdam, NL, building upon a rich body of intellectual property that originated at the Amsterdam Medical Center. Kling’s intuitive but original approach to discovering drugs by investigating cured patients has generated an impressive portfolio of targets and early-stage therapeutic programs, which we believe will form the foundation for a generationally important drug discovery platform.